Completed PHASE4 INTERVENTIONAL 2-arm NCT00818779

Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Heart Disease and Type 2 Diabetes Mellitus

Sponsor: Texas Tech University Health Sciences Center

Conditions Coronary Artery Disease Type 2 Diabetes Mellitus

Interventions Aliskiren Amlodipine

Updated 6 times since 2017 Last updated: Oct 31, 2017 Started: Jan 31, 2008 Primary completion: Aug 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Coronary Artery Disease and Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Texas Tech University Health Sciences Center and has accumulated 6 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Texas Tech University Health Sciences Center

Data source: Texas Tech University Health Sciences Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lubbock, United States